Pharmaceuticals, Biotechnology & Life Sciences

Pharming Group NV: biotech leader in rare‑disease therapies sees high P/E yet stagnant growth; investors weigh its Ruconest success against limited new breakthroughs.

Elite Pharmaceuticals Inc. develops innovative oral controlled‑release drugs, from pain management to cardiovascular therapies, with a focus on growth and R&D.

Fosun Pharma’s new private fund and high‑risk Alzheimer’s drug deal reveal bold bets that could boost or hurt investor value—will the Chengdu‑focused vehicle deliver alpha?

Curis Inc. raises up to $80.8 M in a private placement to fund its cancer‑therapeutic pipeline, notably the promising drug emavusertib, boosting its capital and growth prospects.

Omeros Corp (OMRS) – Seattle‑based biotech developing orthopedics, rheumatology, urology and cardiovascular drugs. Despite a 23% year‑to‑date decline, it remains focused on innovation across 6 therapeutic areas.

AbCellera Biologics Inc. transforms antibody research into next‑generation therapies—discover its stock trends, valuation nuances, and biotech impact.

Fortress Biotech’s stock tops 200‑day MA, yet struggles with negative earnings – investors weigh rising valuation against a growth‑stage biotech’s challenges.

FDA gives Anavex Life Sciences feedback on its Alzheimer’s Phase 2/3 trials – a crucial step that could reshape investor sentiment and the future of precision neuro‑therapy.

GSK’s latest regulatory wins—Shingrix prefilled syringe, bepirovirsen Phase III success, and new approvals for Exdensur and Nucala—signal a broad, growth‑focused portfolio poised to boost vaccine efficiency, advance hepatitis B cures, and expand spe…

Read how Eisai’s subcutaneous Leqembi gained Chinese regulatory acceptance, unlocking a new Alzheimer’s market and boosting its portfolio.